Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study.

Theodora TsioudaKalliopi DomvriEfimia BoutsikouVasileios BikosKrystallia KyrkaKonstantina PapadakiPersefoni PezirkianidouKonstantinos PorpodisAngeliki Cheva

Published in: Journal of personalized medicine (2024)

Our study suggests that the presence of KRAS mutations in advanced NSCLC patients has a poor prognostic value, regardless of their PDL1 expression values, after receiving immunotherapy as first-line treatment.

Keyphrases

squamous cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
poor prognosis
chronic kidney disease
small cell lung cancer
prognostic factors
patient reported outcomes
radiation therapy
locally advanced
lymph node metastasis
smoking cessation
combination therapy